382 related articles for article (PubMed ID: 19712857)
1. C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia.
Justo D; Lachmi S; Saar N; Joffe E; Atzmony L; Mashav N; Henis O; Sade B; Chundadze T; Steinvil A; Paran Y
Eur J Intern Med; 2009 Sep; 20(5):518-21. PubMed ID: 19712857
[TBL] [Abstract][Full Text] [Related]
2. Serum hydrogen sulfide as a novel marker predicting bacterial involvement in patients with community-acquired lower respiratory tract infections.
Chen YH; Yao WZ; Gao JZ; Geng B; Wang PP; Tang CS
Respirology; 2009 Jul; 14(5):746-52. PubMed ID: 19659653
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein levels in patients with chronic obstructive pulmonary disease: role of infection.
Bircan A; Gokirmak M; Kilic O; Ozturk O; Akkaya A
Med Princ Pract; 2008; 17(3):202-8. PubMed ID: 18408388
[TBL] [Abstract][Full Text] [Related]
4. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease.
Molinos L; Clemente MG; Miranda B; Alvarez C; del Busto B; Cocina BR; Alvarez F; Gorostidi J; Orejas C;
J Infect; 2009 Jun; 58(6):417-24. PubMed ID: 19329187
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein is an independent predictor of severity in community-acquired pneumonia.
Chalmers JD; Singanayagam A; Hill AT
Am J Med; 2008 Mar; 121(3):219-25. PubMed ID: 18328306
[TBL] [Abstract][Full Text] [Related]
6. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.
File TM; Monte SV; Schentag JJ; Paladino JA; Klugman KP; Lavin B; Yu VL; Singer ME; Adelman MH
Int J Antimicrob Agents; 2009 Jan; 33(1):58-64. PubMed ID: 18835762
[TBL] [Abstract][Full Text] [Related]
7. Exacerbations of chronic obstructive pulmonary disease.
Wedzicha JA; Donaldson GC
Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein--can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease?
Weis N; Almdal T
Eur J Intern Med; 2006 Mar; 17(2):88-91. PubMed ID: 16490683
[TBL] [Abstract][Full Text] [Related]
9. Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia.
Hohenthal U; Hurme S; Helenius H; Heiro M; Meurman O; Nikoskelainen J; Kotilainen P
Clin Microbiol Infect; 2009 Nov; 15(11):1026-32. PubMed ID: 19548923
[TBL] [Abstract][Full Text] [Related]
10. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome.
Nseir S; Di Pompeo C; Cavestri B; Jozefowicz E; Nyunga M; Soubrier S; Roussel-Delvallez M; Saulnier F; Mathieu D; Durocher A
Crit Care Med; 2006 Dec; 34(12):2959-66. PubMed ID: 17012911
[TBL] [Abstract][Full Text] [Related]
11. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
12. C-terminal provasopressin (copeptin) in patients with community-acquired pneumonia--influence of antibiotic pre-treatment: results from the German competence network CAPNETZ.
Krüger S; Ewig S; Kunde J; Hanschmann A; Marre R; Suttorp N; Welte T;
J Antimicrob Chemother; 2009 Jul; 64(1):159-62. PubMed ID: 19403654
[TBL] [Abstract][Full Text] [Related]
13. The influence of COPD on mortality and severity scoring in community-acquired pneumonia.
Snijders D; van der Eerden M; de Graaff C; Boersma W
Respiration; 2010; 79(1):46-53. PubMed ID: 19372638
[TBL] [Abstract][Full Text] [Related]
14. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease.
Valipour A; Schreder M; Wolzt M; Saliba S; Kapiotis S; Eickhoff P; Burghuber OC
Clin Sci (Lond); 2008 Oct; 115(7):225-32. PubMed ID: 18307413
[TBL] [Abstract][Full Text] [Related]
15. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia.
Perren A; Cerutti B; Lepori M; Senn V; Capelli B; Duchini F; Domenighetti G
Infection; 2008 Mar; 36(2):163-6. PubMed ID: 18330505
[TBL] [Abstract][Full Text] [Related]
16. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD.
Bafadhel M; Clark TW; Reid C; Medina MJ; Batham S; Barer MR; Nicholson KG; Brightling CE
Chest; 2011 Jun; 139(6):1410-1418. PubMed ID: 21030489
[TBL] [Abstract][Full Text] [Related]
17. [C-reactive protein, leukocyte count and ESR in the assessment of severity of community-acquired pneumonia].
Bircan A; Kaya O; Gökirmak M; Oztürk O; Sahin U; Akkaya A
Tuberk Toraks; 2006; 54(1):22-9. PubMed ID: 16615014
[TBL] [Abstract][Full Text] [Related]
18. [The investigation of the relationship between Leptin-insulin resistance and pulmonary function in patients with chronic obstructive pulmonary disease with acute exacerbation].
Pan HY; Lu XZ; Wang DX; Zeng Y; Zhong HB
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Sep; 19(9):519-21. PubMed ID: 17767817
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia.
Bruns AH; Oosterheert JJ; Hak E; Hoepelman AI
Eur Respir J; 2008 Sep; 32(3):726-32. PubMed ID: 18508833
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and Prognostic Value of Inflammatory Parameters Including Neopterin in the Setting of Pneumonia, COPD, and Acute Exacerbations.
Pizzini A; Lunger F; Sahanic A; Nemati N; Fuchs D; Weiss G; Kurz K; Bellmann-Weiler R
COPD; 2017 Jun; 14(3):298-303. PubMed ID: 28548632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
